| 9.1206 0.151 (1.68%) | 01-26 11:08 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.21 | 1-year : | 13.09 |
| Resists | First : | 9.6 | Second : | 11.21 |
| Pivot price | 8.78 |
|||
| Supports | First : | 8.61 | Second : | 8.01 |
| MAs | MA(5) : | 9.02 |
MA(20) : | 8.77 |
| MA(100) : | 9.13  |
MA(250) : | 8.94 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 62.8 |
D(3) : | 69.6 |
| RSI | RSI(14): 56.1 |
|||
| 52-week | High : | 13.15 | Low : | 6.19 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ZVRA ] has closed below upper band by 29.6%. Bollinger Bands are 38.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.61 - 9.65 | 9.65 - 9.69 |
| Low: | 8.84 - 8.89 | 8.89 - 8.93 |
| Close: | 8.89 - 8.97 | 8.97 - 9.04 |
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Mon, 26 Jan 2026
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ - Yahoo Finance
Sat, 24 Jan 2026
Investing in Zevra Therapeutics (NASDAQ:ZVRA) three years ago would have delivered you a 63% gain - Yahoo Finance
Fri, 23 Jan 2026
Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% Higher - Here's What Happened - MarketBeat
Thu, 15 Jan 2026
Is Zevra Therapeutics (ZVRA) Using J.P. Morgan Spotlight To Reframe Its Rare-Disease Investment Story? - Sahm
Thu, 15 Jan 2026
Is Zevra Therapeutics (ZVRA) Using J.P. Morgan Spotlight To Reframe Its Rare-Disease Investment Story? - simplywall.st
Thu, 08 Jan 2026
Zevra Therapeutics to Present at J.P. Morgan 44th Annual Healthcare Conference on January 15, 2026 - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 56 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 71.7 (%) |
| Shares Short | 5,910 (K) |
| Shares Short P.Month | 6,930 (K) |
| EPS | 0.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.36 |
| Profit Margin | 41.8 % |
| Operating Margin | 15.8 % |
| Return on Assets (ttm) | -7.9 % |
| Return on Equity (ttm) | 34.8 % |
| Qtrly Rev. Growth | 605.4 % |
| Gross Profit (p.s.) | 1.2 |
| Sales Per Share | 1.49 |
| EBITDA (p.s.) | -0.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | 19.21 |
| PEG Ratio | 0 |
| Price to Book value | 3.81 |
| Price to Sales | 6.02 |
| Price to Cash Flow | -21.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|